Zurich, September 2014
Application of custom-made culture media for academic research projects: A case study from the Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland.
We are glad to announce a scientific publication by Schibli et al. reporting on the use of modified folate radioconjugates enabling the preclinical application of folic acid-targeted radionuclide therapy in The Journal of Nuclear Medicine (2013), vol. 54, pp. 124-131.
Cell Culture Technologies contributed to the study published by the Center for Radiopharmaceutical Sciences ETH-PSI-USZ at Paul Scherrer Institute and the Department of Chemistry and Applied Sciences of the ETH Zurich by developing a set of modified RPMI 1640 culture media free of folic acid and chromogenic reagents. Such custom-made RPMI 1640 media have been used for over a decade by Roger Schibli and Cristina Mueller’s research group, whose technical collaboration with Cell Culture Technologies started back in year 2000.